<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371110</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 11-1113</org_study_id>
    <secondary_id>HSM#11-01536</secondary_id>
    <nct_id>NCT01371110</nct_id>
  </id_info>
  <brief_title>Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder</brief_title>
  <acronym>IVKetamine</acronym>
  <official_title>Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne Goodman MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obsessive-Compulsive Disorder (OCD) is a chronic and disabling anxiety disorder and a leading
      cause of worldwide disability that presents a significant public health problem. Treatment
      options are limited and many OCD patients fail to respond completely or quickly to standard
      treatments, including pharmacotherapy and psychotherapy. At this time, patients who fail to
      respond to treatment with serotonergic drugs, augmenting antipsychotic agents, and behavioral
      therapy, have few additional treatment options aside from deep brain stimulation. Therefore,
      despite advances in current pharmacological and behavioral treatments, and the utility of
      serotonergic drugs, it is likely that other neurotransmitter systems are involved and that
      targeting these systems may increase treatment efficacy. Despite little evidence for
      serotonergic dysfunction in OCD, there is significant evidence that glutamatergic
      dysregulation may contribute to the development and progression of the disorder. Also,
      preliminary studies suggest that glutamatergic modulators (i.e. riluzole and d-cycloserine),
      particularly agents acting at the NMDA receptor (i.e. memantine), may be useful in OCD. The
      NMDA antagonist, ketamine, has demonstrated rapid effects when delivered as a single
      intravenous (IV) dose in depressed patients. Therefore, the objective of the current study is
      to investigate the safety and efficacy of a single dose of IV ketamine in treatment-resistant
      OCD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the safety and efficacy of a single intravenous (IV) dose of the
      N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, in treatment-resistant
      OCD.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no funding
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCCS) Rating OCD Symptom Severity From Baseline to 24-hours After Ketamine Administration</measure>
    <time_frame>Baseline and 24 Hours</time_frame>
    <description>The primary efficacy outcome is change in the Y-BOCCS rating score on a scale from baseline to 24 hrs post-administration of ketamine.
The 10 Y-BOCCS items are each scored on a four-point scale from 0 = &quot;no symptoms&quot; to 4 = &quot;extreme symptoms.&quot; The sum of the first five items is a severity index for obsessions. The sum of the last five an index for compulsions. A translation of total score into an approximate index of overall severity is: 0-7 - subclinical; 8-15 - mild; 16-23 - moderate; 24-31 - severe; 32-40 - extreme.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Meet Response and Remission</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Percentage of patients who meet response (defined as 25% reduction in Y-BOCCS score) and remission (defined as Y-BOCS score ≤10) criteria at 24 hrs post-infusion and durability of efficacy up to two weeks after administration. Assessments will be performed 24, 48 and 72 hrs post-infusion and after 7, 10, and 14 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>ketamine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, 21-65 years

          -  Women of childbearing potential must agree to use a medically accepted means of
             contraception for the duration of the study

          -  Primary diagnosis of Obsessive-Compulsive Disorder as assessed by the SCID-P, with
             symptoms for at least 1 year (Patients who meet criteria for OCD will be required to
             be medication free or have all psychotropics aside from SSRIs and as needed
             benzodiazepines tapered. Prior to study entry, proscribed psychotropics are tapered,
             and subjects must be on the same SSRI for at least 8 weeks with no change in dose for
             at least 4 weeks and throughout the study. However, subjects will be allowed to use
             benzodiazepines as needed throughout the study.)

          -  History of a failure to respond to at least two (2) adequate pharmacotherapy trials
             and CBT for OCD

          -  Subjects must have scored ≥ 21 on the Y-BOCS at Screening, and to not be in remission
             on Treatment Day #1, and Treatment Day #2

          -  Each subject must have a level of understanding sufficient to agree to all tests and
             examinations required by the protocol and must sign an informed consent document

          -  Subjects must be able to identify a family member, physician, or friend who will
             participate in the Treatment Contract and serve as an emergency contact.

        Exclusion Criteria:

          -  Women who plan to become pregnant within the next six months, are pregnant or are
             breast-feeding

          -  Non-English speakers

          -  Any unstable medical illness including hepatic, renal, gastroenterologic, respiratory,
             cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease

          -  Clinically significant abnormal findings of laboratory parameters, physical
             examination, or ECG

          -  Lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, mental
             retardation, or pervasive developmental disorders

          -  Current evidence of psychotic or manic symptoms

          -  Drug or alcohol abuse or dependence within the preceding 6 months

          -  Lifetime abuse or dependence on ketamine or phencyclidine

          -  Patients judged by study investigator to be at high risk for suicide

          -  Current use of psychotropics other than SSRIs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne K Goodman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine (previously Icahn School of Medicine at Mount Sinai)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyle Lapidus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>(previously Icahn School of Medicine at Mount Sinai)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Centers at Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>September 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2017</results_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Wayne Goodman MD</investigator_full_name>
    <investigator_title>Professor &amp; Chair Psychiatry</investigator_title>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>Obsessive-Compulsive Disorder</keyword>
  <keyword>ketamine</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Mood and Anxiety Disorders Program (MAPs). In addition, referrals from clinicians in the Mount Sinai Medical Center, community clinics, and affiliated hospitals were also sought.</recruitment_details>
      <pre_assignment_details>Eligible participants met treatment-resistant criteria if they failed to respond to ≥ 2 adequate pharmacotherapy trials with SRIs FDA approved medications for OCD with or without adjunctive antipsychotics, as well as cognitive behavioral therapy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine (Randomized Week 1, Cross Over Midazolam Week 3))</title>
          <description>Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
Ketamine: Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.</description>
        </group>
        <group group_id="P2">
          <title>Midazolam (Randomized Wk 1, Cross Over Ketamine Wk 3)</title>
          <description>Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
Midazolam: Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine (Randomized Week 1, Cross Over Midazolam Week 3))</title>
          <description>Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
Ketamine: Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.</description>
        </group>
        <group group_id="B2">
          <title>Midazolam (Randomized Wk 1, Cross Over Ketamine Wk 3)</title>
          <description>Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
Midazolam: Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="49" upper_limit="49"/>
                    <measurement group_id="B2" value="48.5" lower_limit="34" upper_limit="63"/>
                    <measurement group_id="B3" value="48.6" lower_limit="34" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCCS) Rating OCD Symptom Severity From Baseline to 24-hours After Ketamine Administration</title>
        <description>The primary efficacy outcome is change in the Y-BOCCS rating score on a scale from baseline to 24 hrs post-administration of ketamine.
The 10 Y-BOCCS items are each scored on a four-point scale from 0 = &quot;no symptoms&quot; to 4 = &quot;extreme symptoms.&quot; The sum of the first five items is a severity index for obsessions. The sum of the last five an index for compulsions. A translation of total score into an approximate index of overall severity is: 0-7 - subclinical; 8-15 - mild; 16-23 - moderate; 24-31 - severe; 32-40 - extreme.</description>
        <time_frame>Baseline and 24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine (Randomized Week 1, Cross Over Midazolam Week 3))</title>
            <description>Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
Ketamine: Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.</description>
          </group>
          <group group_id="O2">
            <title>Midazolam (Randomized Wk 1, Cross Over Ketamine Wk 3)</title>
            <description>Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
Midazolam: Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCCS) Rating OCD Symptom Severity From Baseline to 24-hours After Ketamine Administration</title>
          <description>The primary efficacy outcome is change in the Y-BOCCS rating score on a scale from baseline to 24 hrs post-administration of ketamine.
The 10 Y-BOCCS items are each scored on a four-point scale from 0 = &quot;no symptoms&quot; to 4 = &quot;extreme symptoms.&quot; The sum of the first five items is a severity index for obsessions. The sum of the last five an index for compulsions. A translation of total score into an approximate index of overall severity is: 0-7 - subclinical; 8-15 - mild; 16-23 - moderate; 24-31 - severe; 32-40 - extreme.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.98" lower_limit="-2.98" upper_limit="-2.98"/>
                    <measurement group_id="O2" value="-2.185" lower_limit="-14.98" upper_limit="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Meet Response and Remission</title>
        <description>Percentage of patients who meet response (defined as 25% reduction in Y-BOCCS score) and remission (defined as Y-BOCS score ≤10) criteria at 24 hrs post-infusion and durability of efficacy up to two weeks after administration. Assessments will be performed 24, 48 and 72 hrs post-infusion and after 7, 10, and 14 days.</description>
        <time_frame>up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine (Randomized Week 1, Cross Over Midazolam Week 3))</title>
            <description>Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
Ketamine: Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.</description>
          </group>
          <group group_id="O2">
            <title>Midazolam (Randomized Wk 1, Cross Over Ketamine Wk 3)</title>
            <description>Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
Midazolam: Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Meet Response and Remission</title>
          <description>Percentage of patients who meet response (defined as 25% reduction in Y-BOCCS score) and remission (defined as Y-BOCS score ≤10) criteria at 24 hrs post-infusion and durability of efficacy up to two weeks after administration. Assessments will be performed 24, 48 and 72 hrs post-infusion and after 7, 10, and 14 days.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
Ketamine: Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.</description>
        </group>
        <group group_id="E2">
          <title>Midazolam</title>
          <description>Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
Midazolam: Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidality</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to limited funding lead to small numbers of subjects analyzed (n=3) compared to what was planned (n=12).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wayne Goodman</name_or_title>
      <organization>Baylor College of Medicine (previously Icahn School of Medicine at Mount Sinai)</organization>
      <phone>713-798-4945</phone>
      <email>wayne.goodman@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

